Principal Securities Inc. Has $195,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Principal Securities Inc. reduced its holdings in Edwards Lifesciences Co. (NYSE:EWFree Report) by 32.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,636 shares of the medical research company’s stock after selling 1,281 shares during the quarter. Principal Securities Inc.’s holdings in Edwards Lifesciences were worth $195,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bowman & Co S.C. grew its stake in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 148 shares during the last quarter. Mount Yale Investment Advisors LLC boosted its position in Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares during the period. Seascape Capital Management raised its position in shares of Edwards Lifesciences by 0.5% during the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after acquiring an additional 174 shares during the last quarter. Finally, Cooper Financial Group lifted its stake in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after acquiring an additional 175 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 over the last three months. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, Piper Sandler increased their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.95.

Get Our Latest Stock Report on EW

Edwards Lifesciences Stock Down 0.8 %

Edwards Lifesciences stock opened at $72.72 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $42.89 billion, a PE ratio of 10.43, a PEG ratio of 4.82 and a beta of 1.11. The firm’s fifty day moving average is $72.83 and its 200 day moving average is $70.13. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.